Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
AACR 2022
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients